3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
4
Phase 1/2
2
Phase 3
1
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Conditions
Pancreatic Neoplasms
16
Colorectal Neoplasms
7
Small Cell Lung Carcinoma
4
Neoplasm Metastasis
4
Stomach Neoplasms
3
Recurrence
3
Biliary Tract Neoplasms
3
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Ovarian Neoplasms
2
Nasopharyngeal Carcinoma
2
Fallopian Tube Neoplasms
2
Cholangiocarcinoma
2
Triple Negative Breast Neoplasms
1
Somatostatinoma
1
Solid Tumor
1
Small Cell Lung Cancer Extensive Stage
1
Small Bowel Adenocarcinoma
1
Rectal Neoplasms
1
Rectal Cancer Patients
1
Pancreatic Ductal Adenocarcinoma
1
Pancreatic Cancer Non-resectable
1
Pancreatic Cancer Metastatic to Liver
1
Pancreatic Adenocarcinoma
1
PDAC - Pancreatic Ductal Adenocarcinoma
1
Osteosarcoma
1
Neoplasms
1
Neoadjuvant Chemotherapy
1
Metastatic Pancreatic Adenocarcinoma
1
Locally Advanced Rectal Cancer (LARC)
1
Interventions
Gemcitabine
53
Bevacizumab
52
Cyclophosphamide
49
Docetaxel
42
Carboplatin
40
pembrolizumab
37
Paclitaxel
36
Fluorouracil
36
Cisplatin
35
Radiotherapy
31
Oxaliplatin
31
Capecitabine
29
Irinotecan
28
Dexamethasone
27
Leucovorin
25
Cetuximab
25
Nivolumab
24
Doxorubicin
22
Drug Therapy
21
Erlotinib Hydrochloride
20
Pemetrexed
19
durvalumab
18
trametinib
17
fludarabine
16
atezolizumab
16
Trastuzumab
16
Sunitinib
16
Rituximab
16
Prednisone
16
Sorafenib
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasms
×
irinotecan sucrosofate
×
Clear all
NCT03837977
2024-12-30
NET02
The Christie NHS Foundation Trust
Phase 2
Completed
58 enrolled